(E/Z)-4-(2-(2-phenylthiophen-3-yl)vinyl)pyrimidin-2-amine | 1068569-93-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (E/Z)-4-(2-(2-phenylthiophen-3-yl)vinyl)pyrimidin-2-amine
• 英文别名: 4-[(E)-2-(2-phenylthiophen-3-yl)ethenyl]pyrimidin-2-amine
• CAS: 1068569-93-6
• 化学式: C₁₆H₁₃N₃S
• 分子量: 279.365
• InChiKey: GZGGZNJXFJYZFL-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-4-甲基嘧啶 、 2-苯基-3-噻吩甲醛; 3-甲酰基-2-苯基噻吩 生成 (E/Z)-4-(2-(2-phenylthiophen-3-yl)vinyl)pyrimidin-2-amine
  参考文献：
  名称：

  Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable

  摘要：

  Tie-2 is a receptor tyrosine kinase which is involved in angiogenesis and thereby growth of human tumours. The discovery and SAR of a novel class of imidazole-vinyl-pyrimidine kinase inhibitors, which inhibit Tie-2 in vitro is reported. Their synthesis was carried out by condensation of imidazole aldehydes with methyl pyrimidines. These compounds are lead-like, with low molecular weight, good physical properties and oral bioavailability. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.106

文献信息

• Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable
  作者：David Buttar、Mike Edge、Steve C. Emery、Martina Fitzek、Cheryl Forder、Alison Griffen、Barry Hayter、Chris F. Hayward、Philip J. Hopcroft、Richard W.A. Luke、Ken Page、John Stawpert、Andy Wright

  DOI：10.1016/j.bmcl.2008.06.106

  日期：2008.8

  Tie-2 is a receptor tyrosine kinase which is involved in angiogenesis and thereby growth of human tumours. The discovery and SAR of a novel class of imidazole-vinyl-pyrimidine kinase inhibitors, which inhibit Tie-2 in vitro is reported. Their synthesis was carried out by condensation of imidazole aldehydes with methyl pyrimidines. These compounds are lead-like, with low molecular weight, good physical properties and oral bioavailability. (C) 2008 Elsevier Ltd. All rights reserved.